Dyadic International, Inc.DYAI
Scheduled
Dyadic International, Inc. IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026
Review the key takeaways and the transcript of this earnings call.
Period 2026
Key takeaways
- Dyadic Applied BioSolutions has transitioned from a research and development organization to a commercial organization with multiple products on the market or in commercialization across life sciences, food nutrition, and bioindustrial.
- The company uses its C1 and Dapabis gene expression platforms to produce proteins and enzymes, with C1 focused on complex proteins such as human therapeutics, monoclonal antibodies, and vaccine antigens, and Dapabis optimized for high-yield, low-cost production in food nutrition and bioindustrial applications.
- Dyadic has begun generating initial product sales, including research-grade products sold through Integrated Biotherapeutics and directly to third parties.
- Dyadic has received about a million for an upfront and milestones related to the launch of a partner’s bovine kymocin, which is currently on the market and generating commercial sales.
- ProLiant launched recombinant human albumin in March of this year, and Dyadic receives a share of the profits.
- Integrated Biotherapeutics has launched six products made using Dyadic’s platform, including DNase-1, human transferrin, growth factors, and albumin-related products.
- The company said initial sales are small, with sampling, testing, and initial pilot sales underway across life sciences, food nutrition, and bioindustrial markets.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring